Publications by authors named "J-C Eicher"
Electronic patient-reported outcome (ePRO) applications promise great added value for improving symptom management and health-related quality of life. The aim of this narrative review is to describe the collection and use of ePROs for cancer survivorship care, with an emphasis on ePRO-symptom monitoring. It offers many different perspectives from research settings, while current implementation in routine care is ongoing.
View Article and Find Full Text PDFBackground: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD).
View Article and Find Full Text PDFBackground Atrial fibrillation (AF) and heart failure (HF) often co-exist and are closely intertwined, each condition worsening the other. The temporal relationships between these two disorders have not yet been fully explored. We aimed to address the outcomes of patients hospitalized with HF and AF based on the chronology of the onset of the two disorders.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the genetic factors influencing plasma levels of Factor VIII (FVIII) and von Willebrand factor (VWF), which are linked to both clotting disorders and thrombosis risk, using data from over 46,000 individuals across various ethnic backgrounds.
- - Researchers discovered 13 new genetic associations with FVIII and VWF levels, including 7 associated with FVIII and 11 with VWF, extending the knowledge beyond previously known variants. Functional tests supported most of these associations.
- - The analysis suggests that higher plasma levels of FVIII may contribute to increased risk of venous thrombosis and coronary artery disease, while elevated VWF levels might heighten the risk of ischemic stroke, highlighting the potential for these proteins
Background: Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared with antiplatelet therapy.
Methods: In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1).